The ChemoTimelines shared task benchmarks methods for constructing timelines of systemic anticancer treatment from electronic health records of cancer patients. This paper describes our methods, results, and findings for subtask 2 -- generating patient chemotherapy timelines from raw clinical notes. We evaluated strategies involving chain-of-thought thinking, supervised fine-tuning, direct preference optimization, and dictionary-based lookup to improve timeline extraction. All of our approaches followed a two-step workflow, wherein an LLM first extracted chemotherapy events from individual clinical notes, and then an algorithm normalized and aggregated events into patient-level timelines. Each specific method differed in how the associated LLM was utilized and trained. Multiple approaches yielded competitive performances on the test set leaderboard, with fine-tuned Qwen3-14B achieving the best official score of 0.678. Our results and analyses could provide useful insights for future attempts on this task as well as the design of similar tasks.

Cancer is one of the leading health challenges for women, specifically breast and ovarian cancer. Early detection can help improve the survival rate through timely intervention and treatment. Traditional methods of detecting cancer involve manually examining mammograms, CT scans, ultrasounds, and other imaging types. However, this makes the process labor-intensive and requires the expertise of trained pathologists. Hence, making it both time-consuming and resource-intensive. In this paper, we introduce a novel vision transformer (ViT)-based method for detecting and classifying breast and ovarian cancer. We use a pre-trained ViT-Base-Patch16-224 model, which is fine-tuned for both binary and multi-class classification tasks using publicly available histopathological image datasets. Further, we use a preprocessing pipeline that converts raw histophological images into standardized PyTorch tensors, which are compatible with the ViT architecture and also help improve the model performance. We evaluated the performance of our model on two benchmark datasets: the BreakHis dataset for binary classification and the UBC-OCEAN dataset for five-class classification without any data augmentation. Our model surpasses existing CNN, ViT, and topological data analysis-based approaches in binary classification. For multi-class classification, it is evaluated against recent topological methods and demonstrates superior performance. Our study highlights the effectiveness of Vision Transformer-based transfer learning combined with efficient preprocessing in oncological diagnostics.

Learning from sparse labels is a challenge commonplace in the medical domain. This is due to numerous factors, such as annotation cost, and is especially true for newly introduced tasks. When dense pixel-level annotations are needed, this becomes even more unfeasible. However, being able to learn from just a few annotations at the pixel-level, while extremely difficult and underutilized, can drive progress in studies where perfect annotations are not immediately available. This work tackles the challenge of learning the dense prediction task of keypoint localization from a few point annotations in the context of 2d carcinosis keypoint localization from laparoscopic video frames for diagnostic planning of advanced ovarian cancer patients. To enable this, we formulate the problem as a sparse heatmap regression from a few point annotations per image and propose a new loss function, called Crag and Tail loss, for efficient learning. Our proposed loss function effectively leverages positive sparse labels while minimizing the impact of false negatives or missed annotations. Through an extensive ablation study, we demonstrate the effectiveness of our approach in achieving accurate dense localization of carcinosis keypoints, highlighting its potential to advance research in scenarios where dense annotations are challenging to obtain.

This study explores a data-driven approach to discovering novel clinical and genetic markers in ovarian cancer (OC). Two main analyses were performed: (1) a nonlinear examination of an OC dataset using autoencoders, which compress data into a 3-dimensional latent space to detect potential intrinsic separability between platinum-sensitive and platinum-resistant groups; and (2) an adaptation of the informative variable identifier (IVI) to determine which features (clinical or genetic) are most relevant to disease progression. In the autoencoder analysis, a clearer pattern emerged when using clinical features and the combination of clinical and genetic data, indicating that disease progression groups can be distinguished more effectively after supervised fine tuning. For genetic data alone, this separability was less apparent but became more pronounced with a supervised approach. Using the IVI-based feature selection, key clinical variables (such as type of surgery and neoadjuvant chemotherapy) and certain gene mutations showed strong relevance, along with low-risk genetic factors. These findings highlight the strength of combining machine learning tools (autoencoders) with feature selection methods (IVI) to gain insights into ovarian cancer progression. They also underscore the potential for identifying new biomarkers that integrate clinical and genomic indicators, ultimately contributing to improved patient stratification and personalized treatment strategies.

For the nearly 20,000 women in the U.S. who receive an ovarian cancer diagnosis each year, artificial intelligence is emerging as a potentially life-saving tool. In a new study led by researchers at Karolinska Institutet in Sweden, AI models did a better job of detecting ovarian cancer than human doctors. The research, which was published in Nature Medicine, tested an AI model's ability to distinguish between benign and malignant lesions on the ovaries, according to a press release. The AI model was trained on more than 17,000 ultrasound images from 3,652 patients across 20 hospitals in eight countries, the release stated. "High-quality diagnostics can become more accessible, particularly in regions with limited access to experienced examiners," said a study author.

This paper presents approaches to compute sparse solutions of Generalized Singular Value Problem (GSVP). The GSVP is regularized by $\ell_1$-norm and $\ell_q$-penalty for $0

Bevacizumab is a widely studied targeted therapeutic drug used in conjunction with standard chemotherapy for the treatment of recurrent ovarian cancer. While its administration has shown to increase the progression-free survival (PFS) in patients with advanced stage ovarian cancer, the lack of identifiable biomarkers for predicting patient response has been a major roadblock in its effective adoption towards personalized medicine. In this work, we leverage the latest histopathology foundation models trained on large-scale whole slide image (WSI) datasets to extract ovarian tumor tissue features for predicting bevacizumab response from WSIs. Our extensive experiments across a combination of different histopathology foundation models and multiple instance learning (MIL) strategies demonstrate capability of these large models in predicting bevacizumab response in ovarian cancer patients with the best models achieving an AUC score of 0.86 and an accuracy score of 72.5%. Furthermore, our survival models are able to stratify high- and low-risk cases with statistical significance (p < 0.05) even among the patients with the aggressive subtype of high-grade serous ovarian carcinoma. This work highlights the utility of histopathology foundation models for the task of ovarian bevacizumab response prediction from WSIs. The high-attention regions of the WSIs highlighted by these models not only aid the model explainability but also serve as promising imaging biomarkers for treatment prognosis.

Computer vision models are increasingly capable of classifying ovarian epithelial cancer subtypes, but they differ from pathologists by processing small tissue patches at a single resolution. Multi-resolution graph models leverage the spatial relationships of patches at multiple magnifications, learning the context for each patch. In this study, we conduct the most thorough validation of a graph model for ovarian cancer subtyping to date. Seven models were tuned and trained using five-fold cross-validation on a set of 1864 whole slide images (WSIs) from 434 patients treated at Leeds Teaching Hospitals NHS Trust. The cross-validation models were ensembled and evaluated using a balanced hold-out test set of 100 WSIs from 30 patients, and an external validation set of 80 WSIs from 80 patients in the Transcanadian Study. The best-performing model, a graph model using 10x+20x magnification data, gave balanced accuracies of 73%, 88%, and 99% in cross-validation, hold-out testing, and external validation, respectively. However, this only exceeded the performance of attention-based multiple instance learning in external validation, with a 93% balanced accuracy. Graph models benefitted greatly from using the UNI foundation model rather than an ImageNet-pretrained ResNet50 for feature extraction, with this having a much greater effect on performance than changing the subsequent classification approach. The accuracy of the combined foundation model and multi-resolution graph network offers a step towards the clinical applicability of these models, with a new highest-reported performance for this task, though further validations are still required to ensure the robustness and usability of the models.

Large pretrained transformers are increasingly being developed as generalised foundation models which can underpin powerful task-specific artificial intelligence models. Histopathology foundation models show promise across many tasks, but analyses have been limited by arbitrary hyperparameters that were not tuned to the specific task/dataset. We report the most rigorous single-task validation conducted to date of a histopathology foundation model, and the first performed in ovarian cancer subtyping. Attention-based multiple instance learning classifiers were compared using vision transformer and ResNet features generated through varied preprocessing and pretraining procedures. The training set consisted of 1864 whole slide images from 434 ovarian carcinoma cases at Leeds Hospitals. Five-class classification performance was evaluated through five-fold cross-validation, and these cross-validation models were ensembled for evaluation on a hold-out test set and an external set from the Transcanadian study. Reporting followed the TRIPOD+AI checklist. The vision transformer-based histopathology foundation model, UNI, performed best in every evaluation, with five-class balanced accuracies of 88% and 93% in hold-out internal and external testing, compared to the best ResNet model scores of 68% and 81%, respectively. Normalisations and augmentations aided the generalisability of ResNet-based models, but these still did not match the performance of UNI, which gave the best external performance in any ovarian cancer subtyping study to date. Histopathology foundation models offer a clear benefit to subtyping, improving classification performance to a degree where clinical utility is tangible, albeit with an increased computational burden. Such models could provide a second opinion in challenging cases and may improve the accuracy, objectivity, and efficiency of pathological diagnoses overall.

AI-driven precision oncology has the transformative potential to reshape cancer treatment by leveraging the power of AI models to analyze the interaction between complex patient characteristics and their corresponding treatment outcomes. New technological platforms have facilitated the timely acquisition of multimodal data on tumor biology at an unprecedented resolution, such as single-cell multi-omics data, making this quality and quantity of data available for data-driven improved clinical decision-making. In this work, we propose a modular machine learning framework designed for personalized counterfactual cancer treatment suggestions based on an ensemble of machine learning experts trained on diverse multi-omics technologies. These specialized counterfactual experts per technology are consistently aggregated into a more powerful expert with superior performance and can provide both confidence and an explanation of its decision. The framework is tailored to address critical challenges inherent in data-driven cancer research, including the high-dimensional nature of the data, and the presence of treatment assignment bias in the retrospective observational data. The framework is showcased through comprehensive demonstrations using data from in-vitro and in-vivo treatment responses from a cohort of patients with ovarian cancer. Our method aims to empower clinicians with a reality-centric decision-support tool including probabilistic treatment suggestions with calibrated confidence and personalized explanations for tailoring treatment strategies to multi-omics characteristics of individual cancer patients.